Stock analysis · Bull Rankings model

ARGX analysis

argenx SEBiotechnology. Scored on the same transparent 7-signal model behind the daily rankings.

ARGX
argenx SE · Biotechnology
FCF
Rev+89.6%A
D/E0.01A
P/E38.1xC+
PEG1.47B
69.6Score
$860.55$53.5B
1Y Target$1,054Analyst consensus · 23 analysts
5Y Target$1,543Compound horizon
10Y Target$2,288Long-dated conviction
FCF
FCF not applicable for this sector (bank / insurer / REIT) or data unavailable
Rev+89.6%FY YoY
A
Revenue +89.6% — hypergrowth, top decile · Computed from last two annual revenue figures (FY YoY).
D/E0.01
A
D/E 0.01 — least levered decile in Healthcare (≈10th pctile)
P/E38.1x
C+
P/E 38.1 — above the Healthcare median (≈75th pctile)
PEG1.47
B
PEG 1.47 — acceptable premium for growth

Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.

Quality-growth score · 69.6
Quality0.72
Growth1.00
Value0.47
Why this score
  • Short track record
Entry · Margin of safety
52-week rangeNear 52-week high
10% off the 12-month high
Why now
ARGX is poised to dominate the autoimmune niche as VYVGART captures expanding gMG and ITP markets, driving an 89.6% YoY revenue surge, sustaining a 31.4% profit margin, and justifying a premium PEG of 1.47—the compounding engine that will keep earnings accelerating.
Moat
VYVGART’s FDA‑approved status and its differentiated FcRn‑targeting mechanism create a high barrier to entry, locking in specialty physicians and insurers while the company’s IP portfolio shields its pipeline of efgartigimod and empasiprubart from rapid copycats.
Risk
The market is pricing growth at a lofty P/E of 38.3, and any slowdown from the current 89.6% revenue growth would expose the stock to valuation compression, especially given the Bull Rankings model’s weak Value pillar (47) and the short track‑record signal; a miss on near‑term sales would trigger a sell‑off.
Horizon
1-3 yr $1,054 (23-analyst consensus) — fundamentals + valuation re-rating. 5 yr $1,543 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $2,288 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Trend
+2.9 over 22 daily scores
From 66.7 (Jun 22) → 69.6 (now)

One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.

Shares to buy
2
Position size
$1,721
3.4% of portfolio
Stop price
$645.41
25% below $860.55
$ at risk if stopped
$430.27
budget $500.00 · 1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

argenx SE (ARGX): score, valuation & FAQ

argenx SE (ARGX) is a Biotechnology company that scores 69.6 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.

Its strongest graded signals are Rev (A) and D/E (A).

Is ARGX a good stock to buy?

Bull Rankings scores ARGX 69.6 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A) and D/E (A). A score is a quantitative screen of argenx SE's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.

Why does ARGX score 69.6 on Bull Rankings?

The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ARGX earns its highest marks on Rev (A) and D/E (A). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.

Is ARGX overvalued or undervalued?

We don't compute a reliable discounted-cash-flow value for ARGX — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.

What are the main risks of investing in ARGX?

The market is pricing growth at a lofty P/E of 38.3, and any slowdown from the current 89.6% revenue growth would expose the stock to valuation compression, especially given the Bull Rankings model’s weak Value pillar (47) and the short track‑record signal; a miss on near‑term sales would trigger a sell‑off.

New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.

Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.

More Healthcare stocks by score

All Healthcare rankings →

Analyze another ticker →